THE US Food and Drug
Administration has approved
Bayer’s Xarelto (rivaroxaban
tablets) for the prophylaxis of deep
vein thrombosis which may lead to
a pulmonary embolism in patients
undergoing knee or hip
replacement surgery.
Xarelto is the only new oral
anticoagulant with US approval in
this indication.
It’s approved for use at a 10mg
dose with one tablet per day for 35
days following hip replacement, or
12 days following knee
replacement surgery.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jul 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jul 11
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.